DEBEL MARLENE
SEC CIK 1770295 · EDGAR
BoughtSold
Most active insiders at MET, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | DEBEL MARLENE | EVP, CRO | — | $1.74M |
| 2 | O'Neill Adrienne Karen | EVP, CAO | — | — |
| 3 | Mumenthaler Christian Stephane | Dir | — | — |
| 4 | Curtis Monica M | EVP, CLO | — | — |
| 5 | Sibblies Shurawl | EVP, Chief HR Off | — | — |
| 6 | Hay Laura J | Dir | — | — |
| 7 | Seitz Michelle | Dir | — | — |
| 8 | PAPPAS BILL | EVP, Gbl Tech, Ops | — | — |
| 9 | WEINBERGER MARK A | Dir | — | — |
| 10 | MCKENZIE DIANA | Dir | — | — |
Transactions 30
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 16:18 | 2026-08-31 | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $95.17 | -4,030 | 150.3K | -3% | -$383.5K | |
| DM | 2026-06-03 16:07 | 2026-06-01 | MET | MetLife | DEBEL MARLENE | EVP, CRO | M - OptEx | $46.17 | +21.3K | 175.7K | +14% | +$984.0K |
| D | 2026-06-03 16:07 | 2026-06-01 | MET | MetLife | DEBEL MARLENE | EVP, CRO | S - Sale+OE | $81.59 | -21.3K | 154.4K | -12% | -$1.74M |
| 2026-03-04 | 2026-03-02 | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $73.24 | -4,133 | 154.4K | -3% | -$302.7K | |
| 2026-02-26 | 2026-02-24 | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $75.34 | -5,624 | 158.5K | -3% | -$423.7K | |
| M | 2026-02-26 | 2026-02-24 | MET | MetLife | DEBEL MARLENE | EVP, CRO | A - Grant | — | +30.0K | 164.1K | +22% | — |
| D | 2026-02-23 | 2026-02-19 | RJF | Raymond James Financial | DEBEL MARLENE | Dir | M - OptEx | $0.00 | +1,253 | 8,820 | +17% | $0 |
| 2025-03-05 | 2025-03-03 | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $85.70 | -2,866 | 134.1K | -2% | -$245.6K | |
| M | 2025-02-27 | 2025-02-25 | MET | MetLife | DEBEL MARLENE | EVP, CRO | A - Grant | — | +41.2K | 121.3K | +51% | — |
| 2025-02-27 | 2025-02-25 | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $82.20 | -12.7K | 137.0K | -8% | -$1.04M | |
| D | 2025-02-24 | 2025-02-20 | RJF | Raymond James Financial | DEBEL MARLENE | Dir | M - OptEx | $0.00 | +1,711 | 7,567 | +29% | $0 |
| DM | 2024-12-17 | 2024-12-13 | MET | MetLife | DEBEL MARLENE | EVP, CRO | M - OptEx | $39.26 | +22.8K | 131.3K | +21% | +$895.4K |
| D | 2024-12-17 | 2024-12-13 | MET | MetLife | DEBEL MARLENE | EVP, CRO | S - Sale+OE | $82.88 | -22.8K | 108.5K | -17% | -$1.89M |
| 2024-03-05 | 2024-03-01 | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $69.73 | -2,741 | 108.5K | -2% | -$191.1K | |
| DM | 2024-02-29 | 2024-02-27 | MET | MetLife | DEBEL MARLENE | EVP, CRO | A - Grant | — | +41.9K | 91.5K | +85% | — |
| D | 2024-02-29 | 2024-02-27 | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $69.16 | -16.2K | 111.2K | -13% | -$1.12M |
| D | 2024-02-26 | 2024-02-22 | RJF | Raymond James Financial | DEBEL MARLENE | Dir | M - OptEx | $0.00 | +1,643 | 5,856 | +39% | $0 |
| 2023-09-05 | 2023-08-31 | MET | MetLife | DEBEL MARLENE | EVP, CRO | A - Grant | — | +7,894 | 85.5K | +10% | — | |
| D | 2023-08-11 | 2023-08-09 | MET | MetLife | DEBEL MARLENE | EVP, CRO | S - Sale+OE | $63.18 | -9,391 | 77.6K | -11% | -$593.3K |
| D | 2023-08-11 | 2023-08-09 | MET | MetLife | DEBEL MARLENE | EVP, CRO | M - OptEx | $45.15 | +10.9K | 87.0K | +14% | +$492.6K |
| DM | 2023-03-02 | 2023-02-28 | MET | MetLife | DEBEL MARLENE | EVP, CRO | A - Grant | — | +37.7K | 60.8K | +163% | — |
| DM | 2023-03-02 | 2023-02-28+ | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $71.66 | -16.9K | 76.1K | -18% | -$1.21M |
| D | 2023-02-27 | 2023-02-23 | RJF | Raymond James Financial | DEBEL MARLENE | Dir | M - OptEx | $0.00 | +1,683 | 4,213 | +67% | $0 |
| D | 2022-08-23 | 2022-08-19 | MET | MetLife | DEBEL MARLENE | EVP, CRO | M - OptEx | $31.15 | +5,513 | 59.4K | +10% | +$171.7K |
| D | 2022-08-23 | 2022-08-19 | MET | MetLife | DEBEL MARLENE | EVP, CRO | S - Sale+OE | $67.60 | -4,060 | 55.3K | -7% | -$274.5K |
| 2022-03-03 | 2022-03-01 | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $64.44 | -1,811 | 53.8K | -3% | -$116.7K | |
| D | 2022-02-25 | 2022-02-24 | RJF | Raymond James Financial | DEBEL MARLENE | Dir | M - OptEx | $0.00 | +1,925 | 2,530 | +318% | $0 |
| D | 2022-02-24 | 2022-02-22 | MET | MetLife | DEBEL MARLENE | EVP, CRO | F - Tax | $68.96 | -4,098 | 55.7K | -7% | -$282.6K |
| DM | 2022-02-24 | 2022-02-22 | MET | MetLife | DEBEL MARLENE | EVP, CRO | A - Grant | — | +16.6K | 48.4K | +52% | — |
| D | 2021-12-03 | 2021-12-02 | RJF | Raymond James Financial | DEBEL MARLENE | Dir | M - OptEx | $0.00 | +605 | 605 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations